---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-115287"
form_type: "8-K"
ticker: "COLL"
cik: "0001267565"
company_name: "COLLEGIUM PHARMACEUTICAL, INC"
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:19:56.439871+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Collegium posts record Q3 revenue $159.3M, up 17%; names Vikram Karnani CEO

## Summary
- Q3 net revenue $159.3M (record), up 17% YoY; GAAP net income $9.3M ($0.27 diluted EPS).
- Adjusted EBITDA $105.1M, up 18% YoY; non-GAAP adjusted EPS $1.61.
- Reaffirms FY2024 guidance: product revenue $620-635M, adjusted EBITDA $395-405M.
- Appoints Vikram Karnani as President and CEO effective Nov 12, 2024; Heffernan remains Chairman.
- Closed Ironshore acquisition (Jornay PM) in Sep 2024, entering ADHD neurology.

## SEC filing metadata
- accession: 0001104659-24-115287
- form_type: 8-K
- ticker: COLL
- cik: 0001267565
- company_name: COLLEGIUM PHARMACEUTICAL, INC
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1267565/000110465924115287/0001104659-24-115287-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1267565/000110465924115287/tm2427748d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-115287
- JSON: https://secwatch.observer/filing/0001104659-24-115287.json
- Plain text: https://secwatch.observer/filing/0001104659-24-115287.txt

## Key facts
- Executive change
  Vikram Karnani was appointed as President and Chief Executive Officer at COLLEGIUM PHARMACEUTICAL, INC.
  - Action: appointed
  - Role: President and Chief Executive Officer
  source text: the Board of Directors (the “Board”) of the Company appointed Vikram Karnani to serve as the Company’s President and Chief Executive Officer, effective November 12, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1267565/000110465924115287/0001104659-24-115287-index.htm
- Executive change
  Vikram Karnani was appointed as member of the Board at COLLEGIUM PHARMACEUTICAL, INC.
  - Action: appointed
  - Role: member of the Board
  source text: Concurrently with his appointment as President and Chief Executive Officer and effective as of the Effective Date, Mr. Karnani will be appointed to serve as a member of the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1267565/000110465924115287/0001104659-24-115287-index.htm
- Executive change
  Michael Heffernan changed role as President and Chief Executive Officer at COLLEGIUM PHARMACEUTICAL, INC.
  - Action: succeeded
  - Role: President and Chief Executive Officer
  source text: succeeding Michael Heffernan, who will continue to serve as the Company’s Chairman of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1267565/000110465924115287/0001104659-24-115287-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.